Medical Cannabinoids

“GACP and GMP”

Products (GACP and GMP)

We produce and distribute high quality cannabis strain as well as various derivates with a high CBD content. In addition we source very rare concentrates from certified suppliers from Switzerland and/or our partners and recognised traders all over the world. The production takes place in compliance with the GACP guidelines, whereby the further steps in the value chain are made under GMP standards. We guarantee complete traceability of our products.

Oils & Terpenes

CBD Extracts  



Medical Flowers  


CBN Extracts

Science Today

CBD – Cannabidiol
“Cannabidiol is a cannabinoid that is thought to have various effects: antioxidant, anti-inflammatory, anti-epileptic, anti-vomiting, anti-anxiety, anti-depressant, anti-psychotic, etc.”(Addiction suisse, 2019, Rapport de recherche n°97, Cannabidiol (CBD): analyse de situation).

CBG – Cannabigerol
“Cannabigerol (CBG) is a non-psychoactive phytocannabinoid produced by the plant Cannabis sativa with affinity to various receptors involved in nociception. As a result, CBG is marketed as an over-the-counter treatment for many forms of pain. However, there is very little research-based evidence for the efficacy of CBG as an anti-nociceptive agent.” (Sepulveda, D. E., Morris, D. P., Raup‐Konsavage, W. M., Sun, D., Vrana, K. E., & Graziane, N. M. (2022). Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy‐induced peripheral neuropathy. European Journal of Pain26(9), 1950-1966.)

CBN – Cannbinol

CBDA – CBD-Carboxylicacid and
THCA – Tetrahydrocannabinolacid

THCV – Tetrahydricannabivarin

CBC – Cannabichromene

Main Benefits of Cannabinoids:

Anxiety Disorders

Regular use of CBD leads to a significant improvement in the symptoms of anxiety disorders.

Arthritis Pain

In order to replace chemical medicine, Cannabinoids are based on 100% natural ingredients with much less side-effects.

Parkinson Disease

Research on this toppic is in progress and results will be expected in the near future.


Seizure Disorder (Epilepsy)

Cost- and time-intensive research is in progress and first results will be expected with patience. There are over 12 components available in natural hemp in order to find a positive results.

Muscle Disorder (Dystonia)

Research on this toppic is in progress and results will be expected in the near future.

Multiple Sclerosis

Research on this toppic is in progress and results will be expected in the near future.

Our Partners

We are globally linked. Our cooperation is an important part to the success of our group of companies. We use synergies to develop new ideas together with our partners. The ideas of today are the projects of tomorrow.

Eidgenössische Technische  Hochschule Zürich
Swiss Federal Institute of Technology Zurich


– ETH Zurich (CH)

Swiss CannaPharmaceutical SA, a subsidiary of Swiss CannaMed SA, has partnered in the following research programme: “CONVERSION OF THC, CBD AND THEIR DERIVATIVES TO CANNABINOL”.
This research, conducted under the direction of Prof. Erick Carreira, ETHZ with his team composed of Ms. Sarah Eichenberger, Mr. Roman Sarott, Mr. Patrick Pfaff and Mr. Remo Roth, was very successful.
A patent in the name of ETH Zurich and Swiss CannaPharmaceutical AG was filed in all European countries as well as the USA.

– Fioricoltura Martinelli, Sementina (CH)

– Canymed, Berlin (D)

– Diapharm GmbH & Co. AG, Münster (D)